Clinical and Molecular Epidemiology of Methicillin-Resistant *Staphylococcus aureus* in New Zealand: Rapid Emergence of Sequence Type 5 (ST5)-SCCmec-IV as the Dominant Community-Associated MRSA Clone

Deborah A. Williamson, Sally A. Roberts, Stephen R. Ritchie, Geoffrey W. Coombs, John D. Fraser, Helen Heffernan

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, Department of Clinical Microbiology, Auckland District Health Board, Auckland, New Zealand, Institute of Environmental Science and Research, Wellington, New Zealand, PathWest Laboratory Medicine, Perth, Australia, Curtin University, Perth, Australia

Abstract

The predominant community-associated MRSA strains vary between geographic settings, with ST8-IV USA300 being the commonest clone in North America, and the ST30-IV Southwest Pacific clone established as the dominant clone in New Zealand for the past two decades. Moreover, distinct epidemiological risk factors have been described for colonisation and/or infection with CA-MRSA strains, although these associations have not previously been characterized in New Zealand. Based on data from the annual New Zealand MRSA survey, we sought to describe the clinical and molecular epidemiology of MRSA in New Zealand. All non-duplicate clinical MRSA isolates from New Zealand diagnostic laboratories collected as part of the annual MRSA survey were included. Demographic data was collected for all patients, including age, gender, ethnicity, social deprivation index and hospitalization history. MRSA was isolated from clinical specimens from 3,323 patients during the 2005 to 2011 annual surveys. There were marked ethnic differences, with MRSA isolation rates significantly higher in Māori and Pacific Peoples. Over the study period, there was a significant increase in CA-MRSA, and a previously unidentified PVL-negative ST5-IV spa t002 clone replaced the PVL-positive ST30-IV Southwest Pacific clone as the dominant CA-MRSA clone. Of particular concern was the finding of several successful and virulent MRSA clones from other geographic settings, including ST93-IV (Queensland CA-MRSA), ST8-IV (USA300) and ST772-V (Bengal Bay MRSA). Ongoing molecular surveillance is essential to prevent these MRSA strains becoming endemic in the New Zealand healthcare setting.

Introduction

The global emergence of community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) over the past two decades has been well described [1]. Of note, the predominant CA-MRSA vary between geographic settings, with USA300 the overwhelmingly dominant CA-MRSA clone in North America, and the ST93 Queensland CA-MRSA clone emerging as the most common CA-MRSA clone in Australia [2,3]. In particular, the epidemic spread of the USA300 clone throughout North America has resulted in considerable morbidity, with several studies describing increasing rates of emergency department attendances and hospitalizations for CA-MRSA-associated skin and soft tissue infections (SSTI) [4,5].

Initial reports of CA-MRSA strains described the emergence of these strains in patients with a lack of traditional epidemiological risk factors for MRSA infection and/or colonization [6]. In particular, patients with CA-MRSA infections were younger, had minimal comorbid illness and lacked prior healthcare contact compared to those patients with infections due to healthcare-associated MRSA (HCA-MRSA) strains [7,8]. Furthermore, distinct socio-demographic associations have been described for CA-MRSA infection, including ethnicity, socioeconomic deprivation and incarceration [1]. Recently however, as the prevalence of CA-MRSA strains has increased, the epidemiological distinction between these strains and HCA-MRSA strains has become less well defined, with numerous reports of nosocomial outbreaks of infections due to CA-MRSA strains [9,10].

In New Zealand, the ST30 South West Pacific (SWP) clone has been the predominant CA-MRSA for the past two decades [11]. Similar to prevalent CA-MRSA strains in other settings, ST30 SWP is characterized by carriage of the type IV SCCmec element, and of the *lukF-PV* and *lukS-PV* genes [12]. However, recent surveillance data suggest that an ST5-SCCmec IV (ST5-IV) CA-MRSA clone may be emerging as a more common cause of CA-MRSA infection in New Zealand [13]. To date however, relatively little is known about the distinct epidemiological associations for
CA-MRSA infection in New Zealand, although a previous study suggested that infection with CA-MRSA strains may be more common in Māori (Indigenous New Zealanders) and Pacific Island populations (Pacific Peoples) [14]. Moreover, the comparative burden and epidemiology of CA-MRSA and HCA-MRSA infections has not previously been described in our geographic setting.

In this context, we sought to (i) describe the clinical and molecular epidemiology of MRSA in New Zealand, and (ii) to describe the emergence of a previously unidentified ST3-IV MRSA strain as the predominant CA-MRSA clone in New Zealand.

This work was presented, in part, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012 in San Francisco.

Methods
Setting, Patients and Data Collection

New Zealand is an island nation located in the South West Pacific, with a resident population of approximately 4.4 million. The population is ethnically diverse, consisting of 67% European, 15% Māori, 10% Asian, 7% Pacific Peoples and 1% of other ethnicities [15].

In New Zealand, a national survey of MRSA isolates is performed in August of each year. All New Zealand community and hospital laboratories refer consecutive, non-duplicate MRSA isolates to the Institute of Environmental Science and Research (ESR), Wellington, New Zealand for molecular typing. As part of this survey, basic patient data is collected, including age, gender and specimen type (clinical vs. screening isolate). We analyzed patient data from each year of the survey between 2005 and 2011. In order to minimize any influence that changes in screening practices may have had on MRSA isolation rates, demographic analysis was restricted to those patients who had a clinical isolate sent for testing. Using hospital admission data recorded by the New Zealand Ministry of Health, the following additional demographic information was extracted about each patient: ethnicity, number of previous hospitalizations in the preceding year, and socioeconomic status based on the New Zealand deprivation index (NZDep). The NZDep score is an area-based measure of deprivation derived from census data, and is based on the following variables of deprivation: household income, household ownership, household occupancy, employment and education levels, access to independent transportation and access to telecommunications. It is expressed as a score between one and ten, a score of ten representing the most deprived neighborhoods [16]. For analysis, ethnicity was grouped into four major ethnic groupings: European, Māori, Pacific Peoples and Asian/other ethnicities. When MRSA isolation was associated with a hospital attendance or admission, all hospital discharge diagnoses related to that event were obtained, coded using the International Classification of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM) codes [17].

Cases were described as community-associated (CA-MRSA) if MRSA was isolated from a patient within 48 hours of hospital admission and/or who: (i) had no history of hospitalization or surgery in the preceding calendar year (ii) did not reside in a long-term care facility (LTCF) and (iii) did not have any prior or current ICD-10-CM discharge diagnoses relating to hemodialysis or implantable devices. Conversely, cases were described as healthcare-associated (HCA-MRSA) if one or more of these risk factors were documented. Similar to previously described methodology [18], we further described healthcare-associated cases as hospital-onset (HCA-HO) or community-onset (HCA-CO) depending on whether the specimen was taken >48 hours or ≤48 hours, respectively, following hospital admission.

Isolate Collection and Analysis

Identification of S. aureus isolates and determination of methicillin resistance was carried out by individual laboratories prior to sending specimens to ESR. Prior to 2009, bacteriophage typing was the routine method used to type MRSA at ESR, as previously described [19]. From 2009 onwards, molecular typing was performed by PCR amplification and sequencing of the polymorphic X region of the staphylococcal protein A (spa) gene, using previously described methods [20]. An internal validation study was conducted in 2009 to ensure concordance between the two typing methods (data not shown). spa sequences were analysed using Ridom StaphType software, Version 2.0.3 (Ridom GmbH, Würzburg, Germany). Clustering of clonal complexes of related spa types (Spa-CCs) was performed using the based upon repeat pattern (BURP) algorithm of the Ridom software [21]. In addition to phage and spa typing, pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST) were used to further define and characterize MRSA strains. PFGE and MLST were performed as previously described [22,23]. SCCmec typing and PCR amplification for detection of lukF-PV and lukS-PV genes was performed on representative isolates from each inferred MLST clonal complex, using previously described methods [24,25].

Statistics and Rates

Period-prevalence rates of MRSA isolation from clinical specimens were calculated per 100,000 population, and were stratified according to age and ethnicity. Population denominator data were obtained from Statistics New Zealand (http://www.stats.govt.nz). Categorical variables were compared using either the χ² or Fisher’s exact test. Non-parametric data were analysed using the Mann-Whitney U test. Odds ratios were calculated with 95% confidence intervals. A regression model was used to determine changes in period-prevalence rates over time. A two-tailed P value of <0.05 was considered significant, and all statistical analysis was performed using SPSS software (Version 19).

Ethics

The Multi-Region Ethics Committee, New Zealand granted ethical approval for this study. As this was an observational study using de-identified patient information, the Ethics Committee waived the need for written informed consent.

Results

Patients and Period-prevalence Rates of MRSA Isolations

MRSA was isolated from clinical specimens from 3,323 patients during the 2005 to 2011 annual surveys. The overall period-prevalence rate of clinical MRSA isolation increased significantly from 8.6 to 18.0 per 100,000 population (P<0.001; Figure 1A). When stratified by age, the highest period-prevalence rates were in the under five and over 65 year age groups (Figure 1A). Full demographic information, including ethnicity was available for 2878 patients. When stratified by ethnicity, period-prevalence rates of MRSA isolations were consistently higher in Māori and Pacific Peoples (Figure 1B).
Of the 3,323 isolates, 1569 (47.2%) were typed using phage typing and 1754 (52.8%) typed using spa typing. Ten major MRSA clonal complex (CC)/sequence types (ST) were identified over the study period (Table 1). The seven most frequent MRSA clones identified, accounting for 85.2% of all clinical MRSA, were ST30-IV (24.8%), ST5-IV (20.4%), ST22-IV (18.8%), ST1-IV (10.2%), ST8-IV (5.9%), ST93-IV (3.3%) and ST239-III (1.8%). Of the 3,323 MRSA isolates, 460 (13.9%) were unable to be assigned a clonal complex or sequence type by phage typing (278 isolates) or spa typing (182 isolates) (Table 1).

An ST5-IV MRSA clone was identified for the first time in the 2005 survey, and rapidly became the predominant CA-MRSA clone in New Zealand. Representative isolates from this clone were negative for the lukF-PV and lukS-PV genes. The relative proportions of the seven predominant MRSA clones isolated from clinical specimens between 2005–2011 are shown in Figure 2.

Notably, the proportion of ST5-IV increased significantly over the study period, from 0.3% in 2005 to 34.7% in 2011 (P<0.001), and the proportions of ST30-IV and ST22-IV decreased significantly from 28.1 to 16.2% (P<0.001) and 37.8 to 8.9% (P<0.001), respectively.

There was an age-related distribution of the seven commonest MRSA clones, with ST22-IV isolated from older patients (median age 79 years, interquartile range [IQR] 62–86 years), followed by ST239-III (median 69 years, IQR 48–79 years), ST8-IV (median 37 years, IQR 18–61 years), ST30-IV (median 27 years, IQR 14–43 years), ST1-IV (median 26 years, IQR 7–53 years) and ST5-IV (median 17 years, IQR 4–42 years).

Isolation of other Emerging MRSA Strains in New Zealand

Fourteen patients with ST772-V MRSA (Bengal Bay MRSA) were identified over the study period (2 patients in 2008; 4 in 2009; 2 in 2010 and 6 in 2011). Ten of these patients were of Indian ethnicity. The spa types associated with ST772-V were t657 (10 isolates), t345 (one isolate) and t5310 (one isolate).

In addition, three patients with CA-MRSA isolates belonging to CC390 were identified in 2011. The associated spa types were t034 (2 isolates) and t011.

Discussion

To our knowledge, this represents the first study to systematically assess the clinical and molecular epidemiology of MRSA from New Zealand. We analyzed seven years of data from our national MRSA survey, and found that, although rates of MRSA isolation were generally low in comparison to other developed countries, there were notable demographic and epidemiological findings.

Most notably, an ST5-IV clone rapidly emerged over the study period and displaced ST30-IV as the dominant CA-MRSA clone. Interestingly, unlike many other CA-MRSA clones, including ST30-IV, this ST5-IV clone characteristically does not harbor the lukF-PV and lukS-PV genes. MRSA strains belonging to ST5 represent a large and diverse group, and are geographically widespread [26,27]. The origin of this recently emerged ST5-IV strain in our region is unclear, but based on studies from other settings it seems probable that this clone emerged from a locally circulating ST5 methicillin-susceptible S. aureus (MSSA) strain which acquired the small, mobile SCCmec-IV element [27]. Future work should attempt to characterize the possible clinical and molecular epidemiology of the ST5-IV clone among CA-MRSA isolates from New Zealand.
| Predicted clonal complex/sequence type | Number analysed by bacteriophage typing between 2005–2008 | Number analysed by spa typing between 2009–2011 | spam types (n) |
|---------------------------------------|----------------------------------------------------------|-------------------------------------------------|----------------|
| ST30 (n = 825)                        | 484                                                      | 341                                             | t019 (309); t975 (5); t1347 (5); t138 (4); t122 (3); t1752 (3); t021 (2); t779 (2); t1133 (1); t1273 (1); t2895 (1); t3723 (1); t4341 (1); t4672 (1); t5994 (1); t6653 (1) |
| ST5 (n = 678)                         | 148                                                      | 530                                             | t002 (461); t405 (23); t548 (10); t062 (7); t306 (7); t1010 (4); t105 (3); t088 (2); t1781 (2); t5677 (2); t1009 (1); t1241 (1); t1311 (1); t1154 (1); t4323 (1); t4685 (1); t5213 (1); t6787 (1) |
| ST22 (n = 625)                        | 404                                                      | 221                                             | t032 (153); t1401 (14); t022 (12); t1274 (5); t852 (4); t5001 (4); t005 (3); t379 (3); t5538 (3); t718 (2); t790 (2); t5785 (2); t7428 (2); t557 (1); t578 (1); t688 (1); t749 (1); t906 (1); t1370 (1); t1415 (1); t1467 (1); t3612 (1); t5836 (1); t605 (1); t6648 (1) |
| ST1 (n = 340)                         | 129                                                      | 211                                             | t127 (178); t701 (11); t267 (5); t386 (3); t591 (1); t1736 (3); t359 (1); t521 (1); t559 (1); t693 (1); t1418 (1); t5100 (1); t5736 (1); t5837 (1) |
| ST8 (n = 196)                         | 58                                                       | 138                                             | t008 (118); t024 (10); t2849 (2); t6229 (2); t711 (1); t610 (1); t627 (1); t1882 (1); t2558 (1); t4919 (1) |
| ST93 (n = 110)                        | 10                                                       | 100                                             | t3949 (68); t202 (30); t1819 (1); t4178 (1); t6487 (1); t7328 (1) |
| ST239 (n = 61)                        | 47                                                       | 14                                              | t037 (10); t631 (1); t4150 (2); t4866 (1) |
| ST772 (n = 14)                        | 2                                                        | 12                                              | t657 (10); t435 (1); t5310 (1) |
| ST36 (n = 11)                         | 9                                                        | 2                                               | t018 (2) |
| CC398 (n = 3)                         | –                                                        | 3                                               | t034 (2); t011 (1) |
| Not determined (n = 460)              | 278                                                      | 182                                             | t185 (24); t576 (16); t375 (14); t189 (11); t437 (9); t524 (8); t282 (6); t148 (4); t065 (3); t179 (3); t186 (3); t213 (3); t270 (3); t1767 (3); t2143 (3); t019 (2); t021 (2); t042 (2); t121 (2); t878 (2); t1781 (2); t9257 (2); t8493 (2); t005 (1); t026 (1); t040 (1); t044 (1); t068 (1); t088 (1); t089 (1); t1271 (1); t394 (1); t442 (1); t586 (1); t638 (1); t688 (1); t690 (1); t771 (1); t786 (1); t791 (1); t855 (1); t1028 (1); t1126 (1); t1300 (1); t1839 (1); t1849 (1); t1895 (1); t2062 (1); t2078 (1); t2085 (1); t2321 (1); t2815 (1); t3979 (1); t4359 (1); t4448 (1); t4467 (1); t5110 (1); t518 (1); t5190 (1); t5562 (1); t5782 (1); t5784 (1); t6256 (1); t668 (1); t7211 (1); t7334 (1); t8349 (1); t9258 (1); t9269 (1); t9508 (1) |
| Total (n = 3323)                      | 1569                                                     | 1754                                            | – |

doii:10.1371/journal.pone.0062020.t001

Figure 2. Relative proportions of methicillin-resistant *Staphylococcus aureus* (MRSA) clones circulating in New Zealand, 2005–2011.
doi:10.1371/journal.pone.0062020.g002
molecular reasons for the successful emergence of this clone in New Zealand.

In addition, we observed a significant increase in the burden of CA-MRSA disease over the study period. In our setting, this was largely due to two CA-MRSA clones, ST30-IV and ST5-IV. The reasons for the marked increase in CA-MRSA over the study period are unclear, but may, in part, reflect the increasing incidence of SSTI in New Zealand over the past decade [28,29]. Of note, the population groups with the highest burden of SSTI in New Zealand, namely Māori and Pacific Peoples, are the same population groups that carry the greatest burden of CA-MRSA disease. A strong association between CA-MRSA disease and distinct indigenous groups in other settings has been previously described, including Aboriginal Australians [30], and American Indians [1]. The reasons for this association are multifactorial, but are likely to involve a combination of poor hygiene, nutrition and domestic crowding [28–30]. Further research should attempt to understand the interaction of host and sociodemographic factors that predispose to CA-MRSA infection in these groups.

We also observed a three-fold increase in the burden of community-associated MRSA disease in patients with prior healthcare exposure (HCA-CO MRSA). The reasons for this significant increase are uncertain, but it seems probable that a number of factors may have contributed, including an increase in the community reservoir of MRSA and changes in the delivery of healthcare, such that many medical treatments and procedures are now undertaken in a community setting. As such, the clinical and molecular epidemiology of HCA-CO MRSA disease may share both community and hospital characteristics. In our data, this was reflected by the specific MRSA clones causing HCA-CO disease; it was notable that ST3-IV and ST30-IV, both clones which are predominantly associated with CA-MRSA, contributed to approximately 40% of HCA-CO MRSA isolates. The infiltration of CA-MRSA clones into the healthcare setting has been recently described, and it has been suggested that CA-MRSA strains may ultimately replace traditional HCA-MRSA strains in the healthcare environment [9]. However, despite the increase in HCA-CO MRSA, we did not observe any increase in HCA-HO MRSA over the study period. This may, in part, be due to local initiatives over the past several years designed to prevent healthcare-associated infections, in particular a national campaign to improve hand hygiene compliance in acute care settings [31]. Future efforts should be directed towards reducing the rate of HCA-HO MRSA even further, in addition to addressing the increasing burden of HCA-CO MRSA.

Interestingly, we also observed the emergence of several clones associated with CA-MRSA disease in other geographic settings, most notably the ST8-IV USA300 clone from North America and the ST93-IV Queensland clone from Australia. Although we did not have specific epidemiological information relating to overseas travel, it seems probable that emergence of these clones in New Zealand was due to sporadic introduction and “spillover” from other settings with ensuing community spread, rather than local emergence of these clones. Of concern was the observation that the USA300 clone accounted for approximately 6% of HCA-HO MRSA isolations over the study period. This successful clone is notable for its apparent transmissibility and ability to harbor several virulence factors [1]. Of further concern was our finding of fourteen MRSA isolates belonging to ST772-V. ST772-V MRSA, also dubbed the “Bengal Bay clone”, is noted for its resistance to multiple antibiotic classes and its ability to harbor several virulence factors including the lukF-PV and lukS-PV genes and the enterotoxin gene cluster (egC) [32]. An epidemiological link with travel to the Indian subcontinent has previously been described for patients from whom ST772 MRSA has been isolated [32]. Although we did not have information related to overseas travel, it is notable that of the fourteen patients with ST772 MRSA in New Zealand, ten (71%) were of Indian ethnicity.

There were a number of limitations with our study. Most notably, we did not have information relating to clinical syndromes associated with specific MRSA clones. Future prospective studies should monitor the type and severity of disease caused by MRSA in our setting, particularly in light of the recent emergence of the lukF-PV/lukS-PV-negative ST3-IV clone. In
### Table 2. Sociodemographic and molecular epidemiological associations of community-associated MRSA (CA-MRSA) and healthcare-associated MRSA (HCA-MRSA) in New Zealand, 2005–2011.

| Category                  | Subcategory          | CA-MRSA (n = 1346) | HCA CO-MRSA (n = 1132) | HCA-HO-MRSA (n = 400) | CA-MRSA vs. HCA CO-MRSA | CA-MRSA vs. HCA HO-MRSA |
|---------------------------|----------------------|--------------------|------------------------|-----------------------|--------------------------|--------------------------|
|                           |                      | P                  | OR (95% CI)            | P                     | OR (95% CI)              |
| Age, median, years (IQR)  |                      | 27 (10–47)         | 50 (19–78)             | 64 (29–80)            | <0.001*                  | –                        |
| Gender                    | Male                 | 692 (51.4)         | 590 (52.1)             | 230 (57.5)            | 0.75                     | 0.97 (0.83–1.14)         | 0.032                   | 0.78 (0.62–0.99) |
|                           | Female               | 654 (49.6)         | 542 (47.9)             | 170 (42.5)            | –                       | –                       | –                       |
| Ethnicity                 | European             | 470 (34.9)         | 559 (49.4)             | 230 (57.5)            | 0.001                   | 0.8 (0.6–0.9)            | 0.001                   | 0.4 (0.3–0.5) |
|                           | Maori                | 466 (34.7)         | 332 (29.3)             | 97 (24.2)             | 0.005                   | 1.3 (1.1–1.5)            | <0.001                  | 1.7 (1.3–2.2) |
|                           | Pacific Peoples      | 345 (25.6)         | 203 (17.9)             | 58 (14.5)             | <0.001                  | 1.6 (1.3–1.9)            | <0.001                  | 2.1 (1.3–2.8) |
|                           | Other                | 61 (4.8)           | 38 (3.4)               | 15 (3.8)              | 0.07                    | 1.5 (0.9–2.2)            | 0.36                    | 1.3 (0.7–2.4) |
| NZDep score               | 1–3 (low deprivation)| 158 (11.7)         | 171 (15.1)             | 70 (17.5)             | 0.014                   | 0.7 (0.6–0.9)            | 0.003                   | 0.6 (0.5–0.9) |
|                           | 4–7 (medium deprivation)| 362 (26.9)     | 311 (27.5)             | 129 (32.2)            | 0.75                    | 0.9 (0.8–1.2)            | 0.036                   | 0.8 (0.6–1.0) |
|                           | 8–10 (high deprivation)| 826 (61.4)        | 650 (57.4)             | 201 (50.3)            | 0.046                   | 1.2 (1.0–1.4)            | <0.001                  | 1.6 (1.2–2.0) |
| MRSA clone                | ST30-IV              | 438 (32.5)         | 232 (20.5)             | 50 (12.5)             | <0.001                  | 2.2 (1.8–2.7)            | <0.001                  | 3.4 (2.4–4.7) |
|                           | ST5-IV               | 335 (24.9)         | 218 (19.3)             | 48 (12.0)             | 0.001                   | 1.4 (1.1–1.7)            | <0.001                  | 2.4 (1.7–3.4) |
|                           | ST22-IV              | 87 (6.5)           | 282 (24.9)             | 154 (38.5)            | <0.001                  | 0.25 (0.2–0.3)           | <0.001                  | 0.1 (0.001–0.2) |
|                           | ST1-IV               | 161 (11.9)         | 106 (9.4)              | 38 (9.5)              | 0.04                    | 1.3 (1.0–1.7)            | 0.17                    | 1.3 (0.9–1.9) |
|                           | ST8-IV               | 80 (5.9)           | 66 (5.8)               | 23 (5.8)              | 0.93                    | 1.0 (0.7–1.5)            | 1.0                     | 1.0 (0.6–1.7) |
|                           | ST93-IV              | 64 (4.8)           | 33 (2.9)               | 9 (2.2)               | 0.02                    | 1.7 (1.1–2.7)            | 0.03                    | 2.2 (1.6–4.7) |
|                           | ST239-III            | 5 (0.4)            | 22 (1.9)               | 29 (7.3)              | <0.001                  | 0.2 (0.1–0.5)            | <0.001                  | 0.05 (0.02–0.1) |

Note: Data are number (%) of patients unless stated otherwise.

*a*Mann-Whitney U test.

Abbreviations: OR, odds ratio; CI, confidence interval; IQR, interquartile range; ST, sequence type; NZDep, New Zealand Deprivation Index score; MRSA, methicillin-resistant *Staphylococcus aureus*.

doi:10.1371/journal.pone.0062020.t002
addition, the data we analyzed was based on annual monthly “snapshot” surveys, rather than continuous surveillance. As such, we had no information on MRSA colonisation/infection from the time periods outside the annual surveys. Despite this limitation however, isolates and data were collected consistently each year, and from all diagnostic microbiology laboratories in New Zealand, thus providing a nationally representative profile of the epidemiology of MRSA. Finally, in this study, we focused exclusively on MRSA. In our setting however, *S. aureus* disease is predominantly due to MSSA strains, which frequently harbor the lukF-PV/lukS-PV genes [25]. Future studies should attempt to assess the clinical and molecular epidemiology of disease caused not only by MRSA, but also by MSSA.

In summary, we found notable temporal and sociodemographic differences in the epidemiology of MRSA in New Zealand. The increase in CA-MRSA was consistent with reports from other settings, and the burden of CA-MRSA was disproportionately carried by the Māori and Pacific Peoples ethnic groups. We identified several MRSA clones not previously known to circulate in New Zealand, including an ST5-IV clone that rapidly displaced ST30-IV as the dominant CA-MRSA clone. Of particular concern was the finding of several successful and virulent MRSA clones from other geographic settings, including ST93-IV (Queensland CA-MRSA), ST8-IV (USA300) and ST772-V (Bengal Bay MRSA). Ongoing molecular surveillance is essential to ensure early identification and tracking of such strains, and to prevent these MRSA strains becoming endemic in the New Zealand healthcare setting.

Acknowledgments

The authors would like to thank all participating New Zealand microbiology laboratories and the technical staff at the Institute of Environmental Science and Research. We also thank Tim Wood for assistance with data analysis.

Author Contributions

Made contribution to manuscript: JDF SRR. Conceived and designed the experiments: DAW HH. Performed the experiments: HH DAW. Analyzed the data: DAW HH. Contributed reagents/materials/analysis tools: DAW HH SAR GC. Wrote the paper: DAW HH.

References

1. David MZ, Daum RS. (2010) Community-associated methicillin-resistant *Staphylococcus aureus* and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23: 616–87.
2. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. (2011) Not community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA)? A clinician’s guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 52: 99–114.
3. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. (2010) Community-associated methicillin-resistant *Staphylococcus aureus*. Lancet 375: 155–68.
4. Heish AL, Chambers HF, Maselli JH, Gonzales R. (2008) National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 168: 1385–91.
5. Frei CR, Makos BR, Daniels KR, Oramasison CJU. (2010) Emergence of community-acquired methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections as a common cause of hospitalization in United States children. J Peadiatr Surg 45: 1967–74.
6. Boucher HW, Corey GR. (2008) Epidemiology of methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis 46: S34–9.
7. Chambers HF. (2001) The changing epidemiology of *Staphylococcus aureus*? Emerg Infect Dis 7: 178–82.
8. Daum RS. (2007) Clinical practice: skin and soft-tissue infections caused by methicillin-resistant *S. aureus*. N Engl J Med 357: 389–90.
9. D’Agata EM, Webb GF, Horn MA, Moellering RC Jr, Ruan S (2009) Modeling the invasion of community-acquired methicillin-resistant *Staphylococcus aureus* into hospitals. Clin Infect Dis 48: 27–34.
10. Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Medillava JR, et al. (2012) Characterization of nasal and blood culture isolates of methicillin-resistant *Staphylococcus aureus* from patients in United States Children. J Antimicrob Agents Chemother 56: 1294–301.
11. Adhikari RP, Cook GM, Lamont I, Lang S, Heffernan H, et al. (2002) Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern meticillin-resistant *Staphylococcus aureus*. J Antimicrob Chemother 50: 825–31.
12. Smith JM, Cook GM. (2005) A decade of community MRSA in New Zealand. Epidemic Infect 133: 899–904.
13. Heffernan H, Bakker S (2011) Annual survey of methicillin-resistant *Staphylococcus aureus* (MRSA). 2011. Institute of Environmental Science and Research. Wellington, New Zealand. Available: http://www.surv.esr.cri.nz/links/epidemiology/Antimicrobial/MRSA/aMRSA_2011.pdf. Accessed 2012 Sep 13.
14. Ritchie SR, Fraser JD, Libby E, Morris AJ, Rainey PB, et al. (2011) Demographic variation in community-based MRSA skin and soft tissue infection in Auckland, New Zealand. NZ Med J 124: 21–30.
15. Statistics New Zealand. 2006 census of populations and dwellings. Available: http://www.stats.govt.nz. Accessed 2012 Sep 13.
16. Salmond C, Creasy P, Sutton FR. (1990) NZDERP1 - A New Zealand index of deprivation. Aust N Z J Public Health 22: 835–37.
17. World Health Organization. International statistical classification of diseases and related health problems. - 10th revision, edition 2010. Available: http://www.who.int/classifications/icd/ICD10Volume_2_en_2010.pdf. Accessed 2012 Sep 13.
18. Kleven RS, Morrison MA, Nadle J, Petit S, Gerselman K, et al. (2007) Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. JAMA 298: 1763–1771.
19. Martin DR, Heffernan HM, Davies HG (1989) Methicillin-resistant *Staphylococcus aureus* - an increasing threat in New Zealand hospitals. N Z Med J 102: 567–9.
20. Strommenger B, Braulke G, Heuck D, Schmied C, Pasemann B, et al. (2008) *spa* typing of *Staphylococcus aureus* as a front-line tool in epidemiological typing. J Clin Microbiol 46: 574–81.
21. Mellmann A, Weniger T, Breserbruggen C, Rottung J, Sammuth M, et al. (2007) Based upon repeat pattern (BURP); an algorithm to characterize the long-term evolution of *Staphylococcus aureus* populations based on *spa* polymorphisms. BMC Microbiol 7: 98.
22. Goering RV. Pulsed-field gel electrophoresis. In: Perrin DH, Tenover FC, Versalovic J, Tang YW, Unger ER, Reltman DA, White TJ, editors. Molecular microbiology: diagnostic principles and practice. Washington: ASM Press; 2004. p.185–99.
23. Einlight MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. J Clin Microbiol 38: 1008–15.
24. Zhang K, McClure J, Elayad S, Louie T, Gouly JN (2005) Novel multiplex PCR assay for characterization and consommatn subtyping of *Staphylococcal serotype chromosome stx types I to V in methicillin-resistant *Staphylococcus aureus*. J Clin Microbiol 43: 5026–33.
25. Mutaia A, Coombs G, Pandey S, Reid P, Ritchie S, et al. (2010) Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible *Staphylococcus aureus* infections in Auckland, New Zealand. J Clin Microbiol 48: 3470–4.
26. Moreeck S, Coombs G, Shore AC, Coleman DC, Aqakpa P, et al. (2011) A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant *Staphylococcus aureus*. PLoS One 6(4): e17936.
27. Nuihel U, Roumagou P, Feldkamp M, Song JH, Ko KS, et al. (2000) Frequent emergence and limited geographic dispersal of methicillin-resistant *Staphylococcus aureus*. Proc Natl Acad Sci U S A 107: 14130–5.
28. O’Sullivan CE, Baker MG, Zhang J (2011) Increasing hospitalizations for serious skin infections in New Zealand children, 1990–2007. Epidemiol Infect 139: 1794–804.
29. Baker MG, Barnard LT, Kovalig A, Verall A, Zhang J, et al. (2012) Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet 379: 1112–9.
30. Tong SY, McDonald MI, Holt DC, Currie BJ (2008) Global Implications of the emergence of community-associated meticillin-resistant *Staphylococcus aureus* in Indigenous populations. Clin Infect Dis 46: 1071–8.
31. Roberts SA, Sieczkowski C, Campbell T, Balla G, Keenan A (2012) Implementing and sustaining a hand hygiene culture change programme at Auckland District Health Board. N Z Med J 125: 75–85.
32. Brennan GI, Shore AC, Corcoran S, Tecklenborg S, Coleman DC, et al. (2012) Emergence of hospital- and community-associated panton-valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus* genotype ST772-MRSA-V in Ireland and detailed investigation of an ST772-MRSAV cluster in a neonatal intensive care unit. J Clin Microbiol 50: 841–7.
Author/s:
Williamson, DA; Roberts, SA; Ritchie, SR; Coombs, GW; Fraser, JD; Heffernan, H

Title:
Clinical and Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus in New Zealand: Rapid Emergence of Sequence Type 5 (ST5)-SCCmec-IV as the Dominant Community-Associated MRSA Clone

Date:
2013-04-25

Citation:
Williamson, D. A., Roberts, S. A., Ritchie, S. R., Coombs, G. W., Fraser, J. D. & Heffernan, H. (2013). Clinical and Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus in New Zealand: Rapid Emergence of Sequence Type 5 (ST5)-SCCmec-IV as the Dominant Community-Associated MRSA Clone. PLOS ONE, 8 (4), https://doi.org/10.1371/journal.pone.0062020.

Persistent Link:
http://hdl.handle.net/11343/259602

File Description:
Published version

License:
CC BY